secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2023-06-12T23:59:59+00:00
Accession:  0001193125-23-165305
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.07, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos Therapeutics stockholders approve reverse stock split and increase in authorized shares
--------------------------------------------------------------------------------

- Stockholders approved a reverse stock split at a ratio of 1-for-5 to 1-for-15, at Board discretion (141.4M for, 38.5M against).
- Authorized common shares increased from 420M to 520M (138.3M for, 41.9M against).
- All seven director nominees elected; RSM US LLP ratified as independent auditor for FY2023 (165.4M for).
- Advisory say-on-pay approved (85.9M for); one-year frequency selected for future advisory votes (94.4M for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523165305/0001193125-23-165305-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523165305/d451080d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-165305

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer